Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.5779
+0.03135.73%
Volume:1.39M
Turnover:802.10K
Market Cap:168.76M
PE:-2.90
High:0.5831
Open:0.5600
Low:0.5527
Close:0.5466
Loading ...

Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial

TIPRANKS
·
19 Nov 2024

Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
19 Nov 2024

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire
·
19 Nov 2024

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
19 Nov 2024

OCGN Stock: Can New Leadership Save This Biotech Company?

TIPRANKS
·
18 Nov 2024

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
16 Nov 2024

BRIEF-Ocugen Inc - Appointed Ramesh Ramachandran To Serve As Co's Principal Financial Officer

Reuters
·
16 Nov 2024

Ocugen Appoints Ramesh Ramachandran as Financial Officer

TIPRANKS
·
16 Nov 2024

Ocugen Inc - Appointed Ramesh Ramachandran to Serve as Co's Principal Financial Officer

THOMSON REUTERS
·
16 Nov 2024

Ocugen’s Promising Pipeline and Strategic Advances Support Buy Rating

TIPRANKS
·
16 Nov 2024

Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
15 Nov 2024

Ocugen: Q3 Earnings Snapshot

Associated Press Finance
·
15 Nov 2024

Ocugen Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024

Ocugen’s Gene Therapies Show Promising Results: Analyst Recommends Buy

TIPRANKS
·
14 Nov 2024

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
14 Nov 2024

Ocugen’s Promising Gene Therapy Advancements and Financial Stability Justify Buy Rating

TIPRANKS
·
13 Nov 2024